Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-interferon plus ART in HIV-HBV coinfection
ChiCTR2200058883Phase 4Recruiting
- Sponsor
- Tianjin Second People's Hospital
- Start
- Apr 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of peginterferon alfa-2b in human immunodeficiency virus infection (HIV), Chronic Hepatitis B (CHB) and HIV and hepatitis B virus coinfection (HIV-HBV) (2 arms), sponsored by Tianjin Second People's Hospital. Primary endpoints: HBsAg seroclearance rate and HBsAg seroconversion rate. Started Apr 2022; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
human immunodeficiency virus infection (HIV)Chronic Hepatitis B (CHB)HIV and hepatitis B virus coinfection (HIV-HBV)
Beyond the preview
Go deeper on ChiCTR2200058883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058883.